
AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Dana, you need to believe the company can turn its focused portfolio and cost initiatives into consistent profitability while managing cyclical auto exposure. The Q1 2026 spike in net income, paired with a continued loss from continuing operations and a delayed 10 Q filing, does not materially change that core near term catalyst or the key risk around earnings quality and customer concentration.
The most relevant recent development here is Dana’s announcement that it could not file its latest 10 Q on time with the SEC. For investors tracking the company’s cost savings, electrification programs, and heavy share buybacks, timely and transparent financial reporting is important context when assessing how much weight to place on an unusually large quarter of reported net income.
But investors should be aware that Dana’s reliance on a concentrated set of large OEM customers could...
Read the full narrative on Dana (it's free!)
Dana's narrative projects $8.3 billion revenue and $398.2 million earnings by 2029.
Uncover how Dana's forecasts yield a $40.71 fair value, a 23% upside to its current price.
Two Simply Wall St Community fair value estimates cluster between US$40.71 and US$47.91, suggesting a fairly tight range of independent views. Against this, the recent earnings volatility and delayed 10 Q filing highlight why you may want to compare several perspectives before deciding how much weight to place on any single set of numbers.
Explore 2 other fair value estimates on Dana - why the stock might be worth just $40.71!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Our daily scans reveal stocks with breakout potential. Don't miss this chance:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com